Emerging Sub-Segments Transforming the T Cell Specific Surface Glycoprotein CD28 Market Outlook

The T Cell Specific Surface Glycoprotein CD28 market is positioned for significant expansion over the next several years. As advances in immunotherapy and biopharmaceutical research accelerate, this sector is set to witness notable developments. Here is an overview of the market's growth prospects, leading players, emerging trends, and detailed segmentation that shape its future trajectory.

Projected Growth and Market Size of the T Cell Specific Surface Glycoprotein CD28 Market
The market for T Cell Specific Surface Glycoprotein CD28 is forecasted to grow strongly, reaching $2.58 billion by 2030. This represents a compound annual growth rate (CAGR) of 9.7%. Key factors propelling this growth include the development of lulizumab pegol and new CD28 inhibitors, an increase in preclinical and clinical trials, and the integration of CD28-targeted therapies into treatments for autoimmune diseases and cancer. Additionally, rising investments in biopharmaceutical research, along with innovations in immunomodulation and monoclonal antibody engineering, are contributing to market expansion. Important trends shaping the market include growing use of flow cytometry and ELISA technologies, expanding applications in immunology and oncology research, ongoing development of novel inhibitors and biobetters, and increased focus on stem cell and autoimmune disease studies, including the incorporation of lulizumab pegol in clinical testing.

Download a free sample of the t cell specific surface glycoprotein cd28 market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Drivers Encouraging Growth in the T Cell Specific Surface Glycoprotein CD28 Market
One of the primary drivers is the advancement and approval of innovative therapies such as lulizumab pegol and other CD28 inhibitors, which offer promising treatment options for autoimmune and cancer conditions. These developments are expanding the scope and effectiveness of immunotherapies targeting CD28 pathways.
Furthermore, the growing number of clinical trials and research efforts focused on CD28-related therapeutics is fueling demand. As biopharmaceutical companies increase investments in immunomodulatory agents and antibody engineering, the potential for new, more effective treatments continues to rise, driving the market forward.

Leading Companies Making an Impact in the T Cell Specific Surface Glycoprotein CD28 Market
Several prominent firms are influential players in this market, including Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton dic*kinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., and Rondo Therapeutics Inc.
A notable collaboration took place in December 2024, when Rondo Therapeutics Inc., a US-based biopharmaceutical company, partnered with Eli Lilly and Company to develop novel CD28 bispecific antibodies targeting solid tumors. This alliance aims to enhance T cell co-stimulation for improved anti-tumor immune responses while reducing immune-related side effects, advancing next-generation immuno-oncology treatments. Eli Lilly and Company is also based in the US and specializes in CD28-focused immuno-oncology therapies.

View the full t cell specific surface glycoprotein cd28 market report:
https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Poised to Influence the T Cell Specific Surface Glycoprotein CD28 Market
Innovative product development, especially combination immunotherapies, is a major focus area for market players. These therapies combine multiple immune-modulating strategies to boost T cell activation and improve treatment outcomes for patients.
For example, in February 2025, Rondo Therapeutics Inc. revealed preclinical data on RNDO 564, a novel CD28 Nectin 4 costimulatory bispecific antibody designed for advanced bladder cancer. This antibody selectively stimulates CD28 on T cells upon binding to Nectin-4-expressing tumor cells, increasing targeted tumor killing while minimizing off-target effects. The encouraging preclinical results support further development as a potential therapy for metastatic urothelial carcinoma patients.

Detailed Segmentation Offering In-Depth Insight Into the T Cell Specific Surface Glycoprotein CD28 Market
The market is segmented into various categories to provide a comprehensive understanding:
1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Western Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Further subcategories include:
- FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing and Partnerships
- FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
- Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
- Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars and Biobetters, Emerging Research Compounds

This structured segmentation highlights the diverse technologies, applications, and players driving the T Cell Specific Surface Glycoprotein CD28 market's evolution and underscores its potential for future breakthroughs.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.